Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.P., M.K.L., J.D.U.); Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China (J.P.).
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.P., M.K.L., J.D.U.); Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China (J.P.)
Drug Metab Dispos. 2021 Oct;49(10):929-937. doi: 10.1124/dmd.121.000557. Epub 2021 Jul 27.
Pregnancy can significantly change the pharmacokinetics of drugs, including those renally secreted by organic anion transporters (OATs). Quantifying these changes in pregnant women is logistically and ethically challenging. Hence, predicting the in vivo plasma renal secretory clearance (CL) and renal CL (CL) of OAT drugs in pregnancy is important to design correct dosing regimens of OAT drugs. Here, we first quantified the fold-change in renal OAT activity in pregnant versus nonpregnant individual using available selective OAT probe drug CL data (training dataset; OAT1: tenofovir, OAT2: acyclovir, OAT3: oseltamivir carboxylate). The fold-change in OAT1 activity during the 2 and 3 trimester was 2.9 and 1.0 compared with nonpregnant individual, respectively. OAT2 activity increased 3.1-fold during the 3 trimester. OAT3 activity increased 2.2, 1.7 and 1.3-fold during the 1, 2, and 3 trimester, respectively. Based on these data, we predicted the CL, CL and total clearance ((CL) of drugs in pregnancy, which are secreted by multiple OATs (verification dataset; amoxicillin, pravastatin, cefazolin and ketorolac, -ketorolac, -ketorolac). Then, the predicted clearances (CLs) were compared with the observed values. The predicted/observed CL, CL, and CL of drugs in pregnancy of all verification drugs were within 0.80-1.25 fold except for CL of amoxicillin in the 3 trimester (0.76-fold) and cefazolin in the 2 trimester (1.27-fold). Overall, we successfully predicted the CL, CL, and CL of drugs in pregnancy that are renally secreted by multiple OATs. This approach could be used in the future to adjust dosing regimens of renally secreted OAT drugs which are administered to pregnant women. SIGNIFICANCE STATEMENT: To the authors' knowledge, this is the first report to successfully predict renal secretory clearance and renal clearance of multiple OAT substrate drugs during pregnancy. The data presented here could be used in the future to adjust dosing regimens of renally secreted OAT drugs in pregnancy. In addition, the mechanistic approach used here could be extended to drugs transported by other renal transporters.
妊娠可显著改变药物的药代动力学,包括那些经有机阴离子转运体(OATs)肾分泌的药物。在孕妇中量化这些变化在操作和伦理上都具有挑战性。因此,预测 OAT 药物在妊娠期间的体内血浆肾分泌清除率(CL)和肾清除率(CL)对于设计 OAT 药物的正确给药方案非常重要。在这里,我们首先使用可用的选择性 OAT 探针药物 CL 数据(训练数据集;OAT1:替诺福韦、OAT2:阿昔洛韦、OAT3:奥司他韦羧酸)量化了妊娠与非妊娠个体之间肾 OAT 活性的变化倍数。与非妊娠个体相比,OAT1 在妊娠第 2 和第 3 期的活性分别增加了 2.9 和 1.0 倍。OAT2 在第 3 期的活性增加了 3.1 倍。OAT3 在妊娠第 1、2 和 3 期的活性分别增加了 2.2、1.7 和 1.3 倍。基于这些数据,我们预测了妊娠期间由多个 OAT 分泌的药物的 CL、CL 和总清除率((CL)(验证数据集;阿莫西林、普伐他汀、头孢唑林和酮咯酸、-酮咯酸、-酮咯酸)。然后,将预测的清除率(CLs)与观察值进行比较。除了妊娠第 3 期阿莫西林的 CL(0.76 倍)和妊娠第 2 期头孢唑林的 CL(1.27 倍)外,所有验证药物的预测/观察到的 CL、CL 和 CL 在 0.80-1.25 倍之间。总的来说,我们成功地预测了妊娠期间由多个 OAT 肾分泌的药物的 CL、CL 和 CL。该方法可用于未来调整在孕妇中给予的经肾分泌的 OAT 药物的剂量方案。